ArticleEnvironmental health : a global access science source2026
Per- and polyfluoroalkyl substances in drinking water and cancer prevalence in the United States.
Article in Environmental health : a global access science source, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundResearch concerning the adverse health effects of per- and polyfluoroalkyl substances (PFAS) continues to grow. With the recent releases of nationwide data on PFAS in drinking water and public drinking water system service boundaries, it is now possible to conduct nationwide geospatial analyses on the relationships between PFAS in drinking water and aspects of health.
objectiveTo examine associations between PFAS in drinking water and cancer history prevalence in the United States.
methodsWe examined cancer history prevalence, at the census tract level, among adults aged ≥ 18 years diagnosed with any cancer in or prior to 2022 using the United States Population Level Analysis and Community EStimates dataset. We obtained data for PFAS in public drinking water from the Fifth Unregulated Contaminant Monitoring Rule (UCMR 5, 2023-ongoing). We used geographic information systems to spatially join water system boundaries (n = 9,733) with census tracts applying population-weighted areal interpolation. We calculated prevalence ratios (PRs) and 95% confidence intervals (CIs) for the associations between PFAS in drinking water and prevalence of cancer history, adjusted for census tract-level sociodemographics, health conditions and behaviors, and environmental factors.
resultsThis analysis included 76,606 census tracts with an average cancer history prevalence of 7.8%. We observed positive associations of cancer history prevalence with PFAS levels in drinking water for 6:2-FTS, PFBA, PFBS, PFHpA, PFHxA, PFHxS, PFNA, PFOA, PFPeA, and PFPeS (p < 0.01). For example, for 6:2-FTS, the adjusted PR comparing the highest quintile (0.0182-0.663 µg/L, population-weighted) to samples below the minimum reporting level (< 0.005 µg/L) was 1.04 (95% CI 1.02-1.07, p < 0.001). No associations were observed for HFPO-DA and PFOS. Models mutually adjusted for correlated PFAS showed generally similar results. SIGNIFICANCE: Higher levels of certain PFAS in drinking water were independently associated with higher cancer history prevalence. Future research should examine the relationships between individual-level cancer outcomes and individual-level exposure to PFAS in drinking water.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.